Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 877-883

  Armstrong, Andrew J ^a   George, Daniel J ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Hormone refractory prostate cancer; Metastatic prostate cancer; Progression free survival; Satraplatin; SPARC trial

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; MITOXANTRONE; OXALIPLATIN; PLACEBO; PLATINUM COMPLEX; PREDNISONE; SATRAPLATIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG INDICATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; KIDNEY FAILURE; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PROGNOSIS; PROSTATE CANCER; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 36448951632     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Armstrong AJ, Carducci MA. 2005. Chemotherapy for advanced prostate cancer. In Principles and Practice of Prostate Cancer. 1st ed. Kirby RS, Partin A, Feneley M, et al. eds. London: Martin Dunitz.
2. Armstrong AJ, Garrett-Mayer ES, de Wit R, et al. 2007. Limitations of the current progression-free survival (PFS) definition in hormone-refractory prostate cancer (HRPC): Benefit associated with continuation of docetaxel beyond TAX327 protocol-defined progression [abstract]. Proceedings of the American Society of Clinical Oncology Prostate Cancer Symposium. In press.
3. Berthold DR, Sternberg CN, Tannock IF. 2005. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol, 23:8247-52.
4. Fokkema E, Groen HJM, Bauer J, et al. 1999. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol, 17:3822-7.
5. Fokkema E, Groen HJM, Helder MN, et al. 2002. JM216-, JM118-, and cisplatin induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human cell lines with different sensitivities to cisplatin. Biochem Pharmacol, 63:1989-96.
6. Jones S, Hainsworth J, Burris HA, et al. 2002. Phase I study of JM-216 (an oral platinum analog) in combination with paclitax0l in patients with advanced malignancies. Invest New Drugs, 20:55-61
7. Latif T, Wood L, Connell C, et al. 2005. Phase II studyi of oral bis(aceto) amn-fine dicloro (cyclohexamine) platinum (IV) (JM216, BMS 182-751) given daily × 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs, 23:79-84.
8. Lin AM, Rosenberg JE, Weinberg VK, et al. 2006. Clinical outcome of taxane-resistant hormone-refractory prostate cancer patients treated with subsequent chemotherapy (ixabepilone or mitoxantrone/prednisone) [abstract]. J Clin Oncol, 24:45 58.
9. McKeage MJ, Raynaud F, Ward J, et al. 1997. Phase I and pharmacokmetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol, 15:2691-700.
10. Melzack R. 1975. The McGill Pain Questionnaire:major properties and scoring methods. Pain, 1:277-99.
11. Moore MR, Troner MB, DeSimone P, et al. 1986. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a southeastern cancer study group trial. Cancer Treat Rep, 70:541-2.
12. Olaussen KA, Dunant A, Fouret P, et al. 2006. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355:983-91.
13. Petrylak D, Sartor O, Witje F, et al. 2007. A Phase III, randomized, double-blind trial of satraplatin and prednisone vs. placebo and prednisone for patients with hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol Prostate Cancer Symposium. Abstract 145.
14. Potti A, Mukherjee S, Petersen R, et al. 2.006. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med, 355:570-80.
15. Saad F, Gleason D, Murray R, et al. 2002. Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with hormone-refractory metastatic prostate cancer. J Natl Cancer Inst, 96:879-82.
16. Scher HI, Warren M, Heller G. 2007. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res, 13:1488-92.
17. Sternberg CN. 2005. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int, 96:990-4.
18. Sternberg CN, Whelan P, Hetherington P, et al. 2005. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 68:2-9.
19. Steinberg CN, Petrylak D, Witjes F, et al. 2007. Satraplatin (S) demonstrates significant clinical benefits for the treatment ofpatients with HRPC: Results of a randomized phase III trial. Proc Am Soc Clin Oncol, 25:5019.
20. Tannock IF, de Wit R, Berry WR, et al. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 351:1502-12.
21. Taplin M, George DJ, Halabi S, et al. 2005. Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in cancer and leukemia group B study 9480. Urology, 66:386-91.
22. Vouillamoz-Lopez S, Buclin T, Lejeune F, et al. 2003. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res, 23:2757-66.
23. Wong E, Giandomenico CM. 1999. Current status of platinum based anti-tumor drugs. Chem Rev, 99:2451-466.